Detail akcie Soligenix Rg online

Business Summary: Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Soligenix Inc revenues decreased from $119K to $0K. Net loss increased 60% to $8.5M. Revenues reflect Specialized BioTherapeutics segment decrease from $2K to $0K. Higher net loss reflects Specialized BioTherapeutics segment loss increase from $1.1M to $3.6M, Public Health Solutions segment loss increase from $120K to $1.6M, Corporate segment loss increase of 45% to $3.4M.